PET/CT scan testing for spread in metastatic prostate cancer
Treatments studied
Part of Cancer clinical trials.
This study tests how well an FTT PET/CT scan can detect and measure metastatic (spread) prostate cancer. It may help your care team decide on the best next treatment plan, especially if you need to change or start therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have a confirmed diagnosis of prostate cancer from tissue testing (biopsy or surgery)
- Your cancer has evidence of spreading, seen on standard scans like CT, MRI, bone scan, or PET/CT
- You are being considered for a new or changed treatment that may include a PARP inhibitor, hormone therapy (ADT), and/or chemotherapy
- You can and will sign a consent form and follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of imaging scan called FAPI PET/CT to see how well it finds the spread of prostate cancer compared to the usual PSMA PET/CT scan. If you join, you'll get an extra scan that might help doctors understand your cancer better and guide treatment decisions.
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.